Views & Analysis
Category :
Views & Analysis
/
Newsletters and Deep Dive digital magazine
It has been nearly two years since Pfizer’s sickle cell disease (SCD) therapy Oxbryta was approved in the UK, but patients will now be able to access the treatment after a
Explore “Innovation as Strategy” framework, providing a guide for employing innovative strategies in life sciences.
In this edition of Deep Dive, Unpacking complex choreography in the biologics patent dance, Alexion examines the urgent need for accelerated access programmes for rare disease treatments, and Putna
It will come as no surprise to anyone in the healthcare space that doctors today are under an inordinate amount of pressure.
We are living in an era of unprecedented advances in cancer treatments with transformative therapies being regularly approved.
Accelerate your capsid and payload design with the 4th Next Generation Gene Therapy Vectors Summit (June 12-14, Boston), the industry’s only hub for covering the latest advances and innovations in
WASHINGTON, D.C., April 30, 2024 –The Food and Drug Administration’s (FDA) final rule has reclassified laboratory developed tests (LDTs) as medical devices, according to Avalere.
Get in-depth news, opinions and features on pharma and healthcare sent straight to your inbox